About Neuland Labs
Neuland Labs is a company based in Hyderabad (India) founded in 1984 by Davuluri Sucheth Rao. It operates as a Professional Services and HealthTech. The company has 1,790 employees as of March 31, 2024. Neuland Labs has completed 1 acquisition, including Arch Pharmalabs. Neuland Labs offers products and services including Generic APIs, CDMO Services, and Peptide Development. Neuland Labs operates in a competitive market with competitors including Laurus Labs, Symbiotec, Provepharm Life Solutions, SeQuent and Sterling Pharma Solutions, among others.
- Headquarter Hyderabad, India
- Employees 1790 as on 31 Mar, 2024
- Founders Davuluri Sucheth Rao
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Neuland Laboratories Ltd.
-
Annual Revenue
$170.19 M (USD)-5.27as on Mar 31, 2025
-
Net Profit
$30.43 M (USD)-13.32as on Mar 31, 2025
-
EBITDA
$36.75 M (USD)-29.62as on Mar 31, 2025
-
Latest Funding Round
$18.35 M (USD), Post-IPO
May 24, 2018
- Investors
-
Employee Count
1790
as on Mar 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Neuland Labs
Neuland Labs is a publicly listed company on the NSE with ticker symbol NEULANDLAB in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Neuland Labs
Neuland Labs offers a comprehensive portfolio of products and services, including Generic APIs, CDMO Services, and Peptide Development.
Generic APIs are manufactured for various therapeutic categories.
Custom drug development services are provided end-to-end comprehensively.
Peptide synthesis services are offered at various scales.
People of Neuland Labs
Unlock access to complete
Unlock access to complete
Funding Insights of Neuland Labs
- Total Funding Total Funding
- Total Rounds 2
- Last Round Post-IPO — $18.4M
-
First Round
First Round
(12 Dec 2012)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2018 | Amount | Post-IPO - Neuland Labs | Valuation |
investors |
|
| Dec, 2012 | Amount | Post-IPO - Neuland Labs | Valuation |
investors |
Investors in Neuland Labs
Neuland Labs has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Evolvence.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Holding company focused on asset management, education and retail
|
Founded Year | Domain | Location |
Investments & Acquisitions by Neuland Labs
Neuland Labs has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Arch Pharmalabs.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
API manufacturer & supplier, also offering custom synthesis and contract manufacturing services
|
1999 |
Financial Statements - Neuland Labs
Neuland Labs Comparisons
Competitors of Neuland Labs
Neuland Labs operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Laurus Labs, Symbiotec, Provepharm Life Solutions, SeQuent and Sterling Pharma Solutions, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Pharmaceutical and biotechnology company
|
|
| domain | founded_year | HQ Location |
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
|
|
| domain | founded_year | HQ Location |
APIs and drug products are developed and valorized in pharmaceuticals.
|
|
| domain | founded_year | HQ Location |
APIs are developed and manufactured for therapeutic areas.
|
|
| domain | founded_year | HQ Location |
Contract development, manufacturing, and analytical services for APIs are offered.
|
|
| domain | founded_year | HQ Location |
Drug discovery and development service provider
|
Frequently Asked Questions about Neuland Labs
Neuland Labs was founded in 1984 and raised its 1st funding round 28 years after it was founded.
Neuland Labs is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Davuluri Sucheth Rao is the current CEO of Neuland Labs. They have also founded this company.
As of Mar 31, 2024, the latest employee count at Neuland Labs is 1,790.
Annual revenue of Neuland Labs is $170.19M as on Mar 31, 2025.
Neuland Labs is involved in the development and manufacturing of active pharmaceutical ingredients (APIs) and offers contract development and manufacturing organization (CDMO) services. The company serves over 500 pharmaceutical and biotech organizations across 80 countries. Operations are focused on generic APIs, custom drug development, and peptide synthesis. Solutions are provided for early-stage drug development through commercial manufacturing, emphasizing quality, compliance, and innovation. Sectors served include healthcare and pharmaceuticals, with a commitment to sustainability and environmental responsibility integrated into processes.
Neuland Labs's top competitors include Laurus Labs, Symbiotec and Sterling Pharma Solutions.
Neuland Labs offers Generic APIs, CDMO Services, and Peptide Development.
Yes, Neuland Labs is publicly traded on NSE under the ticker symbol NEULANDLAB.
Neuland Labs has made 1 acquisition, including Arch Pharmalabs.
Neuland Labs has 1 investor. Key investors include Evolvence.
The ticker symbol of Neuland Labs is NEULANDLAB on NSE.